Literature DB >> 28969559

Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance.

Kanika Vasudeva1, Pratibha Chaurasia1, Sulena Singh2, Anjana Munshi1.   

Abstract

BACKGROUND AND
OBJECTIVE: Stroke is one of the leading causes of death. There has been compelling evidence that stroke has a genetic component. Genetic variants not only influence susceptibility to stroke but have also been found to alter the response to pharmacological agents and influence the clinical outcome of the disease. Stroke patients are treated with antiplatelet drugs like aspirin and clopidogrel to prevent a secondary stroke. In spite of the fact that many new antiplatelet drugs have been developed, aspirin is still considered as a golden standard for the antiplatelet therapy. Aspirin achieves its action by inhibiting platelet cyclooxygenase (COX) system involved in the formation of thromboxane A2 (TXA2). TXA2 triggers reactions leading to platelet activation and aggregation. This Non-steroidal anti-inflammatory drug (NSAID) acts by inhibiting this mediator. Despite the demonstrated benefits of aspirin, many patients develop secondary stroke or other vascular events, an observation that has led to the concept of aspirin resistance. Studies have demonstrated that adequate antiplatelet effects are not achieved in 5-45% patients suggesting that many individuals are aspirin resistant. Aspirin resistance is multifactorial in origin. A genetic component has also been suggested, and variants in more than a dozen genes involved in absorption, distribution, metabolism, excretion (ADME) and pharmacodynamics of aspirin have been shown to be responsible for aspirin resistance. In addition, the patients on aspirin treatment also face adverse drug reactions on account of genetic variation.
CONCLUSION: The present review has been compiled with an aim to revisit all the studies related to genetic variation contributing to aspirin resistance as well as adverse drug reactions. The output of high throughput genomic technology like genome wide association studies and others has also been discussed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Adverse drug reactions; aspirin resistance; non-steroidal anti inflammatory drug; pharmacogenetics; stroke; therapeuticzzm321990agents

Mesh:

Substances:

Year:  2017        PMID: 28969559     DOI: 10.2174/1871527316666171002115633

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  4 in total

1.  Danhong Injection and Trimetazidine Protect Cardiomyocytes and Enhance Calcium Handling after Myocardial Infarction.

Authors:  Jingjing Zhang; Xiaolu Shi; Jinhuan Gao; Rui Zhou; Feifei Guo; Yi Zhang; Fangfang Fan; Qu Zhai; Mingjie Sun; Hongjun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-15       Impact factor: 2.629

Review 2.  The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review.

Authors:  Małgorzata Szczuko; Igor Kozioł; Dariusz Kotlęga; Jacek Brodowski; Arleta Drozd
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 3.  Genome-Wide Studies in Ischaemic Stroke: Are Genetics Only Useful for Finding Genes?

Authors:  Cristina Gallego-Fabrega; Elena Muiño; Jara Cárcel-Márquez; Laia Llucià-Carol; Miquel Lledós; Jesús M Martín-Campos; Natalia Cullell; Israel Fernández-Cadenas
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

4.  Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI.

Authors:  Lijie Zhang; Ying Lv; Jianyu Dong; Nana Wang; Zhan Zhan; Yuan Zhao; Shanshan Jiang
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.